<DOC>
	<DOCNO>NCT02890849</DOCNO>
	<brief_summary>The detection tissue PD-L1 immunohistochemistry Non-small cell lung cancer ( NSCLC ) important role guide treatment immune detection point . At time , tissue detection time-consuming laborious , liquid biopsy reflect information tumor tissue , PD-L1 mRNA plasma exosomes ( pExo ) expect simple , rapid , non-invasive mean detection . The project plan explore consistency analysis PD-L1 expression level detect cancer tissue pExo.We design detected expression level PD-L1 mRNA protein cancer tissue detect expression level PD-L1 mRNA pExo.By use variance analysis repeat measure design information . Thus explore consistency analysis PD-L1 expression level detect tissue pExo , guide clinical practice radiotherapy combine immunotherapy .</brief_summary>
	<brief_title>Clinical Research Consistency Analysis PD-L1 Cancer Tissue Plasma Exosome</brief_title>
	<detailed_description />
	<criteria>1 . Pathological histology and/or cytology confirm malignant tumor ; 2 . Voluntarily enrolled participate , good compliance , cooperate experimental observation , sign inform consent . 1 . Vital organ ( e.g. , heart , liver , kidney ) serious dysfunction ; 2 . Patients history autoimmune disease ; 3 . Patients participate clinical trial time ; 4 . Other case researcher believe patient participate present trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>